Active Ingredients: Amoxicillin
Several clinical investigations have compared the clinical and microbiologic efficacy of fosfomycin with respect to other first line antimicrobials for uncomplicated cystitis.
However, a recent meta-analysis of 27 trials found no difference in efficacy between fosfomycin and other antibiotics for the treatment of cystitis and found that fosfomycin was associated with significantly fewer adverse reactions in pregnant women.
In addition, in a recent randomized single-blinded study, single dose fosfomycin at 3 g was as effective as ciprofloxacin, at 500 mg twice a day for 5 days, in the treatment of acute uncomplicated cistitis.
Additional usefulness of fosfomycin is in the treatment of multidrug-resistant organisms. Several in vitro studies have demonstrated that fosfomycin is active against vancomycin-resistant Staphylococcus aureus, and ESBL-producing Gram-negative rods.
Two studies evaluated oral treatment with fosfomycin trometamol for lower urinary tract infections with ESBL-producing E.
Treatment with fosfomycin was associated with clinical cure in 75 of the 80 93.
In adition, observational studies have also shown that fosfomycin can be effective in the treatment of urinary tract infections due to K. Finally, fosfomycin appears to have minimal propensity for collateral damage.
This asumption is suspected by the high rate of E. The convenience of a single-dose regimen, in vitro activity against resistant Gram-negative rods, and minimal propensity for collateral damage make fosfomycin a useful choice in the treatment of acute uncomplicated cystitis, particularly in areas, like Spain, where other antimicrobials are no longer useful for empirical therapy due to an unacceptable rate of resistances.
Thus, fosfomycin trometamol 3 g in a single dose is an appropriate choice for therapy in uncomplicated cystitis due to minimal resistance and propensity for collateral damage, but it appears to have a slightly inferior efficacy compared with other satadard short-course regimens A-I.
Nitrofurantoin, belonging to a group of synthetic nitrofuran, was initially introduced as a microcrystalline form. In 1967 a macrocrsitalline form with improved gastrointetinal tolerance became available.
For therapy of UTIs nitrofurantoin in the macrocrystalline formulation is given orally at 50 to 100 mg four times daily. The dose of the mixture of microcrystalline and macrocrystalline formulation is 100 mg twice a day. This latter presentation is not commercialized in Spain.Como alternativa, a continuacin son los ms comunes de los grupos de. Lincomicina, amoxicilina precauciones Antes de comenzar su tratamiento con Amoxicilina generico.
The mechanisms of bacterial activity appears to involve multiple sites, including inhibition of ribosomal translation, bacterial DNA damage, and interference with the Krebs cycle.